Literature DB >> 2809510

Antibodies to cachectin/tumor necrosis factor reduce interleukin 1 beta and interleukin 6 appearance during lethal bacteremia.

Y Fong1, K J Tracey, L L Moldawer, D G Hesse, K B Manogue, J S Kenney, A T Lee, G C Kuo, A C Allison, S F Lowry.   

Abstract

Cytokines secreted in response to invading micro-organisms are important mediators of detrimental hemodynamic and metabolic changes in the host. To test whether cachectin/TNF plays a role in triggering release of other cytokines in the setting of infection, anesthetized baboons were passively immunized against systemic cachectin/TNF before infusion of a LD100 dose of live Escherichia coli. Bacteremia led to significant increases in circulating levels of cachectin/TNF, IL-1 beta, and IL-6. Although bacterial endotoxin/lipopolysaccharide is a potent stimulus for the synthesis and release of IL-1 and IL-6 in vitro, specific neutralization of cachectin/TNF in vivo with mAb pretreatment significantly attenuated both the IL-1 beta and the IL-6 responses despite fulminant overwhelming bacteremia. These data suggest that cachectin/TNF is essential for the initiation or amplification of IL-1 and IL-6 release during lethal gram-negative septic shock syndrome.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2809510      PMCID: PMC2189514          DOI: 10.1084/jem.170.5.1627

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  25 in total

1.  Use of glucose oxidase, peroxidase, and O-dianisidine in determination of blood and urinary glucose.

Authors:  A S HUGGETT; D A NIXON
Journal:  Lancet       Date:  1957-08-24       Impact factor: 79.321

2.  On the fragmentation of monoclonal IgG1, IgG2a, and IgG2b from BALB/c mice.

Authors:  P Parham
Journal:  J Immunol       Date:  1983-12       Impact factor: 5.422

3.  Response of the subhuman primate in gram-negative septicemia induced by live Escherichia coli.

Authors:  J L Pool; S E Owen; F K Meyers; J J Coalson; D D Holmes; C A Guenter; L B Hinshaw
Journal:  Surg Gynecol Obstet       Date:  1971-03

4.  Cloning, sequence and expression of two distinct human interleukin-1 complementary DNAs.

Authors:  C J March; B Mosley; A Larsen; D P Cerretti; G Braedt; V Price; S Gillis; C S Henney; S R Kronheim; K Grabstein
Journal:  Nature       Date:  1985 Jun 20-26       Impact factor: 49.962

5.  Passive immunization against cachectin/tumor necrosis factor protects mice from lethal effect of endotoxin.

Authors:  B Beutler; I W Milsark; A C Cerami
Journal:  Science       Date:  1985-08-30       Impact factor: 47.728

6.  A peroxidase-coupled method for the colorimetric determination of serum triglycerides.

Authors:  M W McGowan; J D Artiss; D R Strandbergh; B Zak
Journal:  Clin Chem       Date:  1983-03       Impact factor: 8.327

7.  Interleukin 6, the third mediator of acute-phase reaction, modulates hepatic protein synthesis in human and mouse. Comparison with interleukin 1 beta and tumor necrosis factor-alpha.

Authors:  G Ramadori; J Van Damme; H Rieder; K H Meyer zum Büschenfelde
Journal:  Eur J Immunol       Date:  1988-08       Impact factor: 5.532

8.  Human tumor necrosis factor. Production, purification, and characterization.

Authors:  B B Aggarwal; W J Kohr; P E Hass; B Moffat; S A Spencer; W J Henzel; T S Bringman; G E Nedwin; D V Goeddel; R N Harkins
Journal:  J Biol Chem       Date:  1985-02-25       Impact factor: 5.157

9.  The complex pattern of cytokines in serum from patients with meningococcal septic shock. Association between interleukin 6, interleukin 1, and fatal outcome.

Authors:  A Waage; P Brandtzaeg; A Halstensen; P Kierulf; T Espevik
Journal:  J Exp Med       Date:  1989-01-01       Impact factor: 14.307

10.  Interleukin 1 potentiates the lethal effect of tumor necrosis factor alpha/cachectin in mice.

Authors:  A Waage; T Espevik
Journal:  J Exp Med       Date:  1988-06-01       Impact factor: 14.307

View more
  167 in total

Review 1.  Back to the future: antibody-based strategies for the treatment of infectious diseases.

Authors:  H Barbaros Oral; Cüneyt Ozakin; Cezmi A Akdiş
Journal:  Mol Biotechnol       Date:  2002-07       Impact factor: 2.695

2.  Dose-dependent increase in plasma interleukin-6 after recombinant tumour necrosis factor infusion in humans.

Authors:  N Sheron; J N Lau; J Hofmann; R Williams; G J Alexander
Journal:  Clin Exp Immunol       Date:  1990-12       Impact factor: 4.330

3.  Uroepithelial cells are part of a mucosal cytokine network.

Authors:  S Hedges; W Agace; M Svensson; A C Sjögren; M Ceska; C Svanborg
Journal:  Infect Immun       Date:  1994-06       Impact factor: 3.441

4.  Effects of fibronectin and group B streptococci on tumour necrosis factor-alpha production by human culture-derived macrophages.

Authors:  E B Peat; N H Augustine; W K Drummond; J F Bohnsack; H R Hill
Journal:  Immunology       Date:  1995-03       Impact factor: 7.397

5.  Induction of urinary interleukin-1 (IL-1), IL-2, IL-6, and tumour necrosis factor during intravesical immunotherapy with bacillus Calmette-Guérin in superficial bladder cancer.

Authors:  E C De Boer; W H De Jong; P A Steerenberg; L A Aarden; E Tetteroo; E R De Groot; A P Van der Meijden; P D Vegt; F M Debruyne; E J Ruitenberg
Journal:  Cancer Immunol Immunother       Date:  1992       Impact factor: 6.968

6.  Local cytokine production in a murine model of Escherichia coli pyelonephritis.

Authors:  H S Rugo; P O'Hanley; A G Bishop; M K Pearce; J S Abrams; M Howard; A O'Garra
Journal:  J Clin Invest       Date:  1992-03       Impact factor: 14.808

7.  Activated macrophages depress the contractility of rabbit carotids via an L-arginine/nitric oxide-dependent effector mechanism. Connection with amplified cytokine release.

Authors:  C Bernard; B Szekely; I Philip; E Wollman; D Payen; A Tedgui
Journal:  J Clin Invest       Date:  1992-03       Impact factor: 14.808

8.  Interrelations between interleukin-6, interleukin-1 beta, plasma C-reactive protein values, and in vitro C-reactive protein generation in patients with inflammatory bowel disease.

Authors:  M Z Mazlam; H J Hodgson
Journal:  Gut       Date:  1994-01       Impact factor: 23.059

9.  Protection against endotoxic shock and lipopolysaccharide-induced local inflammation by tetracycline: correlation with inhibition of cytokine secretion.

Authors:  L Shapira; W A Soskolne; Y Houri; V Barak; A Halabi; A Stabholz
Journal:  Infect Immun       Date:  1996-03       Impact factor: 3.441

10.  The role of bactericidal/permeability-increasing protein in the treatment of primate bacteremia and septic shock.

Authors:  M A Rogy; H S Oldenburg; S E Calvano; W J Montegut; S A Stackpole; K J Van Zee; M N Marra; R W Scott; J J Seilhammer; L L Moldawer
Journal:  J Clin Immunol       Date:  1994-03       Impact factor: 8.317

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.